Dr Reddy's Laboratories enters into a llcensing agreement with Gilead Sciences for Remdesivir

Dr Reddy’s will receive technology transfer from Gilead for manufacturing of this drug

Dr Reddy's Laboratories Ltd., Remdesivir, Gilead Sciences, US Food and Drug Administration, Licensing agreement, Technology transfer, Emergency Use Authorization, COVID-19

Dr Reddy's Laboratories Ltd. has announced that it has entered into a non-exclusive licensing agreement with Gilead Sciences, Inc. (Gilead) that will grant Dr Reddy’s the right to register, manufacture and sell Gilead’s investigational drug, Remdesivir, a potential treatment for Covid-19, in 127 countries including India.

Dr Reddy’s will receive technology transfer from Gilead for manufacturing of this drug. Dr Reddy’s would need to do the manufacturing scale up and obtain regulatory approval for marketing of this drug in respective countries.

Remdesivir is an investigational antiviral therapy developed by Gilead, received Emergency Use Authorization (EUA) by the US. Food and Drug Administration (USFDA) to treat Covid-19.